Literature DB >> 14715824

Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients.

Rossella Elisei1, Agnese Vivaldi, Laura Agate, Eleonora Molinaro, Chiara Nencetti, Lucia Grasso, Aldo Pinchera, Furio Pacini.   

Abstract

Thyroglobulin (Tg) is a glycoprotein specifically synthesized by follicular thyroid epithelium. After thyroidectomy and remnant (131)I ablation, serum Tg is a specific and sensitive marker for the presence of thyroid cancer tissue, and its measurement is fundamental in the follow-up of patients affected by differentiated thyroid carcinomas (DTCs), being even more sensitive than diagnostic whole-body scan. Unfortunately, serum Tg measurement becomes useless in approximately 15-25% of DTC cases who are positive for anti-Tg antibodies that interfere with the Tg measurement. In these cases, Tg mRNA measurement has been proposed as an alternative to serum Tg determination. The aim of this study was to verify the sensitivity and specificity of Tg mRNA measurement, performed by quantitative real-time RT-PCR, in a series of 100 subjects (80 DTC patients and 20 controls). From our data, the sensitivity and the specificity of the blood Tg mRNA measurement are 82.3 and 24.2%, respectively, with a positive predictive value and a negative predictive value of 65.6 and 43.7%, respectively. The comparison of the Tg mRNA with the serum Tg, measured by both chemiluminescent and ultrasensitive ELISA methods, confirmed the low specificity of the Tg mRNA assay. The hypothesis that Tg mRNA detectable levels could be predictive of future recurrences is not supported by the long follow-up (median, 7 yr; range, 3-29 yr) of our disease-free patients, who did not develop any recurrences in their clinical history. Moreover, nine disease-free patients, who showed positive levels of Tg mRNA (11.8-336 pg equivalents/ micro g RNA), were confirmed to be serum Tg free, both in basal conditions and after recombinant human TSH stimulation, 4 yr after the Tg mRNA detection. In conclusion, we demonstrated that the Tg mRNA assay is of poor utility in the follow-up of DTC patients. On the contrary, serum Tg measurement is a very sensitive and specific thyroid tumor marker, and we recommend that the follow-up of patients affected by DTC must be performed using serum Tg rather than blood Tg mRNA measurement.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14715824     DOI: 10.1210/jc.2003-031341

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

Review 1.  Advances in the follow-up of differentiated or medullary thyroid cancer.

Authors:  Rossella Elisei; Aldo Pinchera
Journal:  Nat Rev Endocrinol       Date:  2012-04-03       Impact factor: 43.330

2.  Peripheral blood levels of thyroglobulin mRNA and serum thyroglobulin concentrations after radioiodine ablation of multinodular goiter with or without pre-treatment with recombinant human thyrotropin.

Authors:  I G S Rubio; M N C Silva; M Knobel; R Romão; R Possato; E M M S Gebrin; C Buchpiguel; G Medeiros-Neto
Journal:  J Endocrinol Invest       Date:  2007 Jul-Aug       Impact factor: 4.256

3.  Oncofoetal fibronectin--a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma.

Authors:  E Hesse; P B Musholt; E Potter; T Petrich; M Wehmeier; R von Wasielewski; R Lichtinghagen; T J Musholt
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

Review 4.  Detection of circulating Tg-mRNA in the follow-up of papillary and follicular thyroid cancer: how useful is it?

Authors:  F A Verburg; C J M Lips; E G W M Lentjes; J M H de Klerk
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

5.  Circulating thyrotropin receptor messenger ribonucleic acid is not an effective marker in the follow-up of differentiated thyroid carcinoma.

Authors:  Surasawadee Ausavarat; Jiraporn Sriprapaporn; Busara Satayaban; Wanna Thongnoppakhun; Aunchalee Laipiriyakun; Boontham Amornkitticharoen; Rujaporn Chanachai; Chaveevan Pattanachak
Journal:  Thyroid Res       Date:  2015-08-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.